The suboxone market offers therapeutic benefits in the treatment of opioid addiction through its combination of buprenorphine and naloxone. Suboxone helps in relieving extreme opioid withdrawal symptoms and cravings in patients undergoing medication-assisted treatment (MAT) for opioid use disorder. The drug works by occupying opioid receptors in the brain, thus blocking the euphoric and sedative effects of illicit opioids. In 2021,
The global suboxone market is estimated to be valued at US$ 6,163.9 million in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030).
Key Takeaways
Key players operating in the Suboxone market are Major players operating in the global suboxone market include Indivior PLC, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Rhodes Pharmaceuticals L.P., Alvogen, Sun Pharmaceutical Industries Ltd., Alkem Labs, and Hikma Pharmaceuticals PLC. Amneal Pharmaceuticals LLC and Mylan N.V. are other prominent generic drug makers in the market.
Suboxone Market Demand is being driven by the rising government initiatives and funding for opioid dependence treatment programs, amid the growing global opioid addiction epidemic. According to the WHO, around 34 million people suffer from opioid use disorders worldwide.
Technological advancements like the development of sublingual filmstrips and tablets has enhanced patient adherence to suboxone treatment compared to conventional sublingual tablets. Companies are also investing in developing combination products with naloxone to reduce risk of intravenous drug abuse.
Market Trends
Growing availability of generic versions of suboxone: Patent expiries of branded Suboxone in major markets is expected to boost availability of low-cost generic versions, improving access and affordability of MAT.
Rising adoption of digital health tools: Integration of telehealth and remote patient monitoring tools in opioid addiction care programs is allowing wider reach of MAT, supporting market growth of drugs like suboxone.
Market Opportunities
Expanding access in underserved markets: Large untapped growth potential exists in developing regions of Asia Pacific and Latin America with rising abuse but low availability of evidence-based addiction treatment options.
Combination therapies: Combining suboxone with other drugs, digital therapies and supportive programs can offer synergistic treatment benefits over suboxone monotherapy.
Impact of COVID-19 on Suboxone Market Growth
The COVID-19 pandemic led to significant challenges for the Suboxone market. Lockdowns and social distancing measures disrupted supply chains and production. This led to shortages of Suboxone strips and tablets in many regions. Recovery programs also faced difficulties with reduced in-person services.
However, telehealth emerged as a new platform for opioid addiction treatment during the pandemic. Many drug treatment centers expanded telehealth and online counseling options. This ensured continued access to medication-assisted treatment. Regulatory changes allowed prescribing Suboxone through telehealth visits. Healthcare systems also prioritized treating opioid addiction through distribution of take-home doses of Suboxone.
As the pandemic recedes, greater acceptance of telehealth is likely to remain. Hybrid treatment models combining in-person and virtual care will optimize access. Long wait times for admission earlier may reduce. Government funding and insurance coverage for tele-addiction services indicate commitment to remote treatment access. Overall, COVID-19 has accelerated digitalization of addiction care. This will support the Suboxone market’s growth in the long run by overcoming geographic and social barriers.
Geographical Regions with Highest Suboxone Market
In terms of value, North America has concentrated the highest Suboxone market share globally. This is attributed to the region’s high prevalence of opioid addiction disorders and favorable reimbursements for medication-assisted treatment. Within North America, the United States accounts for the lion’s share of the market owing to the scale of its opioid crisis. Government initiatives to expand medication-based treatment under the SUPPORT Act bolster the U.S. market.
Fastest Growing Region for Suboxone Market
Europe is projected as the fastest growing regional market for Suboxone over the forecast period. Increasing prioritization of addressing opioid addiction as a public health issue drives market growth. Countries like Germany, United Kingdom and France demonstrate high growth owing to rising opioid misuse amid coordinated policy action to scale up medication-assisted therapies. Favorable pricing and reimbursement further encourage buprenorphine-naloxone adoption to manage substance use disorders in the European region.
Get More Insights – Suboxone Market
Get This Report in Japanese Language –サブオキソン市場
Get This Report in Korean Language –서복손 마켓
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)